ABO血型不合与急性白血病异基因造血细胞移植结局的关联
基于国际血液与骨髓移植研究中心(CIBMTR)数据库,纳入2008至2018年间接受异基因造血细胞移植的4946例成人急性髓系白血病或急性淋巴细胞白血病患者,按供受者ABO状态分为相合、次要不合、主要不合和双向不合四组。多变量分析显示,主要ABO不合与总生存更差、血小板植入更差和原发植入失败更高相关,而复发及急慢性移植物抗宿主病与ABO状态无显著关联。
要点
- 主要ABO不合与总生存更差相关(HR 1.16,95%CI 1.05-1.29;p=0.005)。
- 主要ABO不合与血小板植入更差(HR 0.83,95%CI 0.77-0.90;p<0.001)及原发植入失败更高(HR 1.60,95%CI 1.12-2.30;p=0.01)相关。
- 复发、急性移植物抗宿主病III-IV级和慢性移植物抗宿主病与ABO状态无显著关联。
核心结论
- 供受者ABO状态与急性白血病异基因造血细胞移植后的生存及其他移植后结局独立相关。
- 作者认为这强调在供者选择流程中考虑ABO状态及其在急性白血病中的影响的重要性。
研究设计与样本
- 利用国际血液与骨髓移植研究中心(CIBMTR)数据库,纳入2008至2018年间接受异基因造血细胞移植、年龄≥18岁的急性髓系白血病或急性淋巴细胞白血病患者。
- 共4946例符合条件患者,按供受者ABO状态分为相合、次要不合、主要不合和双向不合四组。
主要发现
- 4946例中ABO相合2741例(55.4%),次要不合1030例(20.8%),主要不合899例(18.1%),双向不合276例(5.6%)。
- 多变量分析中,与ABO相合相比,主要ABO不合与总生存更差相关(HR 1.16,95%CI 1.05-1.29;p=0.005)。
- 主要ABO不合与血小板植入更差相关(HR 0.83,95%CI 0.77-0.90;p<0.001),与原发植入失败更高相关(HR 1.60,95%CI 1.12-2.30;p=0.01)。
- 复发、急性移植物抗宿主病III-IV级和慢性移植物抗宿主病与ABO状态无显著关联。
- 供者年龄与结局无显著关联,受者年龄较大与生存更差和非复发死亡相关。
临床怎么用
- 作者认为供受者ABO状态与生存及其他移植后结局独立相关,强调在供者选择流程中考虑ABO状态及其在急性白血病中的影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). While many factors influence the outcomes of allo-HCT, the independent impact of donor-recipient ABO mismatching remains unclear. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified patients aged ≥18 years with AML or ALL who underwent allo-HCT between 2008 and 2018. Our objectives were to analyze the outcomes of allo-HCT based on the donor-recipient ABO status (match, minor mismatch, major mismatch, bidirectional mismatch). Among 4946 eligible patients, 2741 patients (55.4%) were ABO matched, 1030 patients (20.8%) had a minor ABO mismatch, 899 patients (18.1%) had a major ABO mismatch, and 276 patients (5.6%) had a bidirectional ABO mismatch. In multivariable analyses, compared to ABO matched allo-HCT, the presence of a major ABO mismatch was associated with worse overall survival (HR 1.16, 95% CI 1.05-1.29; p = 0.005), inferior platelet engraftment (HR 0.83, 95% CI 0.77-0.90; p < 0.001), and higher primary graft failure (HR 1.60, 95% CI 1.12-2.30, p = 0.01). Relapse, acute graft versus host disease (GVHD) grades III-IV and chronic GVHD were not significantly associated with ABO status. While donor age was not significantly associated with outcomes, older recipient age was associated with worse survival and non-relapse mortality. Our study demonstrates that donor-recipient ABO status is independently associated with survival and other post-transplantation outcomes in acute leukemia. This underscores the importance of considering the ABO status in donor selection algorithms and its impact in acute leukemia.
引用
- Guru Murthy GS, Logan BR, Bo-Subait S, et al. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. Am J Hematol. 2023. PMID: 36606713. doi:10.1002/ajh.26834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。